Compare Ecolab Inc. (ECL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs TransMedics Group Inc — how do they compare? Ecolab Inc. trades at $280.68 (market cap $79.79B), while TransMedics Group Inc trades at $87.2 (market cap $3.10B). The key difference: Ecolab Inc. is far larger — about 25.7× TransMedics Group Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ECL | TMDX | |
|---|---|---|
Market Cap | $79.79B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $308.35 | $150.42 |
52-Week Low | $245.73 | $61.99 |
Enterprise Value | $88.57B | $3.49B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $281.17, down 1.14% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance to $8.05-$8.25. Revenue growth remains steady at 5% organic, supported by pricing gains and volume increases. Valuation ratios are elevated with a P/E of 38.21, reflecting premium pricing for consistent performance.
Outlook is positive with a consensus price target of $327.90, implying 16.6% upside. Risks include high valuation sensitivity and rising input costs. The stock offers growth potential from digital expansion and recent CoolIT acquisition, but investors should monitor margin pressures and debt levels.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
